NEW YORK (GenomeWeb News) – Genelabs Technologies this week said CFO Matthew Loar will resign on Sept. 1. The company said he has taken a job at an undisclosed biotech company.
James Smith, Genelabs’ president and CEO, will assume Loar’s duties until a permanent replacement is found.
In the same statement, Genelabs said it hired Peter Young to be its vice president of biology. Young comes to Genelabs from Celera Genomics, where he held the same position.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.